Skip to content
Review Open access

Breast cancer brain metastasis: mechanisms, emerging biomarkers, and therapeutic opportunities.

2026 · American Journal of Cancer Research · Vol 16 9, pp. 3921-3957 · 0 citations
Medicine

TL;DR

This review examines the biological bottlenecks that precede a detectable brain lesion: survival in the circulation, interaction with the cerebral endothelium, passage across the blood-brain barrier, persistence in neural tissue, and intracranial outgrowth.

Abstract

Breast cancer brain metastasis (BCBM) is a clinically distinct form of metastatic breast cancer that causes substantial neurological morbidity and mortality. This review examines the biological bottlenecks that precede a detectable brain lesion: survival in the circulation, interaction with the cerebral endothelium, passage across the blood-brain barrier (BBB), persistence in neural tissue, and intracranial outgrowth. We emphasize how astrocytes, microglia, neurons, stromal cells, and the nutrient environment of the brain shape these events and influence treatment response. These biological features also shape disease assessment. Magnetic resonance imaging defines lesion burden but cannot reliably determine molecular status, whereas tissue sampling is invasive and plasma biomarkers may underrepresent disease confined to the central nervous system. We therefore examine the complementary roles and current limitations of tissue reassessment, blood- and cerebrospinal fluid-based liquid biopsy, molecular imaging, and artificial intelligence-assisted image analysis. Experimental evidence is interpreted according to the questions that individual models can answer. Spontaneous, intravascular, and intracranial models retain different stages of the metastatic cascade, while immunocompetent, patient-derived xenograft, and organoid systems differ in their ability to reproduce immune interactions and patient heterogeneity. Treatment is considered by subtype and clinical setting, including the need for immediate local control, intracranial disease burden, leptomeningeal involvement, previous therapy, and extracranial disease status. Clinical evidence is most developed for human epidermal growth factor receptor 2 (HER2)-positive BCBM, whereas treatment of hormone receptor-positive/HER2-negative disease and triple-negative breast cancer remains more dependent on local therapy and systemic indications derived from extracranial disease. Linking brain-specific mechanisms with biomarker selection, model interpretation, and subtype-guided treatment may improve the translation of experimental findings into clinically meaningful strategies.

Read PDF

Similar papers

Open access Sep 2026

A Tri-Phasic View of the Microenvironment in Breast Cancer Brain Metastasis

Breast cancer brain metastasis (BCBM) is driven by microenvironmental remodeling across three interconnected phases: the primary tumor microenvironment (TME) licenses dissemination, the pre-metastatic niche (PMN) primes the brain, and the established metastatic niche sustains outgrowth through central nervous system (C...

Zi-Qing Yuan, Yan-Qing Wu, Yue Zhao et al. · 0 citations
Review Open access Sep 2026

Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research

Glioblastoma (GBM) remains a major challenge in neuro-oncology, associated with a high rate of mortality despite decades of intensive research and therapeutic advancements, underscoring the urgent need for innovative preclinical platforms that can more accurately recapitulate the biological and pathological features of...

Reza Shirazi Nia, Jian Lu, D. de Vega et al. · 0 citations
Review Open access Oct 2026

Liver Metastases from Colorectal Cancer: From Pathogenesis to Current Treatment

Colorectal cancer (CRC) remains one of the most frequently diagnosed malignancies worldwide, and colorectal cancer liver metastasis (CRLM) represents a major cause of CRC‐related mortality. The liver provides a highly specialized environment that can be remodeled into a metastatic niche, where anatomical structure, met...

Jia-Liang Fan, Hui-Ru Zhang, De-Yang Kong et al. · 0 citations
Review Open access Sep 2026

Stemness-Associated Biomarkers in Breast Cancer Liver Metastasis: Hepatic Adaptation, Prognostic Relevance, and Monitoring

The clinical assessment, treatment, and prognostic evaluation of breast cancer liver metastasis (BCLM) remain clinically challenging. Hepatic involvement is often identified only after substantial intrahepatic tumor burden, radiologically evident parenchymal involvement, abnormal liver function, or symptoms attributabl...

Bin Hu, Jing Hou, Shi-Hang Hu · 0 citations
Review Open access Nov 2026

Neuro-immune-tumor microenvironment interactions in pancreatic cancer: mechanisms and targeted therapeutic strategies

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is highly aggressive and resistant to conventional treatment. Perineural invasion (PNI) and bidirectional neuroimmune signaling contribute to tumor progression, immune evasion, pain, and treatment resistance. This review integrates the morpholog...

Fu-Qiang Tian, Yan Cai, Yue-Hong Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.